Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
CRESCENT BIOPHARMA, INC. President and COO Jonathan McNeill reported an open-market sale of 20,549 Ordinary Shares at a weighted average price of $17.99 per share. According to the filing, the shares were automatically sold to cover tax withholding obligations from vesting restricted stock units under a pre-arranged Rule 10b5-1 instruction. After these tax-related sales, McNeill directly holds 139,158 Ordinary Shares.
CRESCENT BIOPHARMA, INC. director and Chief Executive Officer Joshua T. Brumm reported an automatic sale of ordinary shares primarily related to equity compensation taxes. On June 22, 2026, he sold 42,305 ordinary shares at a weighted average price of $17.99 per share.
According to the disclosure, these shares were automatically sold to satisfy tax withholding obligations from the settlement of restricted stock units granted on December 15, 2025 and March 17, 2025, under a Rule 10b5-1 instruction adopted on February 28, 2026. Following the transaction, Brumm directly holds 281,212 ordinary shares of Crescent Biopharma.
Crescent Biopharma is registering for resale up to 19,580,843 ordinary shares. This prospectus supplement updates the March 3, 2026 prospectus to cover resale by selling securityholders of 19,580,843 Ordinary Shares, including specified tranches held by Fairmount Healthcare Fund II L.P.
The supplement references a Form 8-K and an amendment to the Form 10-Q, notes the Nasdaq closing price of $17.69 on June 18, 2026, and reports that 27,571,935 Ordinary Shares were outstanding as of April 24, 2026 / April 7, 2026. The resale is by selling securityholders (no proceeds to the company stated here).
Crescent Biopharma, Inc. filed Amendment No. 1 to its quarterly report for the period ended March 31, 2026 to add previously omitted disclosure about Rule 10b5-1 trading arrangements. The amendment does not change any financial statements or other disclosures from the original filing.
The company reports that on February 25, 2026 seven senior executives adopted pre-arranged “sell-to-cover” Rule 10b5-1 instructions to sell ordinary shares only as needed to cover tax withholding on vesting of restricted stock units and performance stock units granted under company equity plans. As of April 24, 2026, 27,571,935 ordinary shares were outstanding.
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director David Charles Lubner received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director Alexandra Balcom received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036.
The grant vests in full on the earlier of June 2, 2027 or the date of the company’s next annual meeting of shareholders, as long as she continues serving the company. Following this grant, she holds options on 11,050 shares directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
CRESCENT BIOPHARMA, INC. director Susan Moran received a grant of options to buy 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to her continued service, leaving her with 11,050 derivative securities directly held after this transaction.
CRESCENT BIOPHARMA, INC. reported an insider equity award involving investment entities affiliated with Fairmount Funds. A stock option for 11,050 ordinary shares was granted at an exercise price of $17.0100 per share, expiring on June 2, 2036.
The option was awarded to Peter Harwin, who holds it for one or more investment vehicles managed by Fairmount Funds Management LLC. It vests in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service. Fairmount, Harwin, and Tomas Kiselak state they disclaim beneficial ownership beyond any pecuniary interest.
Crescent Biopharma, Inc. reported the results of its annual general meeting of shareholders held on June 2, 2026. Shareholders elected Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE as Class II directors to serve until the 2029 annual general meeting.
Investors also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on a non-binding basis the compensation of named executive officers. Shareholders recommended holding future advisory votes on executive pay every year, and the Board agreed to follow an annual frequency.